Chronic myeloid leukemia (CML) is a clonal myeloproliferative disorder. CML cells contain a BCR-ABL gene, not typically found in normal cells that produce a protein (BCR-ABL) causing CML cells to proliferate. CML occurs in three phases: chronic, accelerated and blast crisis. Disease staging is primarily based on percent of blasts in the blood and bone marrow. Most cases of CML are diagnosed in chronic phase (CP). The major objective in CML clinical management is to prevent progression from chronic to accelerated and blast crisis phases. While earlier treatments, such as cytoreductive chemo- and interferon therapies increased overall survival rates among patients, the advent of tyrosine-kinase inhibitors (TKIs) have changed the CML treatment landscape. Despite the widespread use of these therapies, there have also been associated side effects that could potentially affect its use. Also it is necessary to avoid all deaths and complications related to the treatment, by limiting as much as possible the side-effects of the treatment while ensuring the compliance of the patients. The aim of this work was to measure the serum estrogen and its soluble receptor levels in patients with chronic myeloid leukemia in order to extrapolate their possible clinical significance. The present study included 40 (20 males and 20 females) healthy volunteers clinically free from any disease, 40 (20 males and 20 females) patients of newly diagnosed CML. Blood samples were collected from all subjects and the level of serum estrogen (E2) and serum soluble estrogen receptor (ER) were measured by enzyme linked immunosorbent assay (ELISA). The level of serum E2 (pg/ml) in both male and female patients groups with CML was significantly higher than in control group. The level of serum ER (ng/ml) in both male and female patients groups with CML was significantly lower than in control group. Estimating the serum level of E2 and soluble ER is of informative diagnostic value. Estimation serum level of E2 and soluble ER in patients with CML is of value in deciding use of antiestrogen as therapeutic target in treatment protocol.

慢性粒细胞白血病 (CML) 是一种克隆性骨髓增生性疾病。CML 细胞含有 BCR-ABL 基因，这种基因通常不存在于产生导致 CML 细胞增殖的蛋白质 (BCR-ABL) 的正常细胞中。CML 发生在三个阶段：慢性、加速和急变危象。疾病分期主要基于血液和骨髓中原始细胞的百分比。大多数 CML 病例在慢性期 (CP) 中被诊断出来。CML 临床管理的主要目标是防止从慢性进展到加速和急变期。虽然细胞减灭性化疗和干扰素疗法等早期治疗提高了患者的总体存活率，但酪氨酸激酶抑制剂 (TKI) 的出现改变了 CML 的治疗前景。尽管这些疗法被广泛使用，还有可能影响其使用的相关副作用。还必须通过尽可能限制治疗的副作用同时确保患者的依从性来避免与治疗相关的所有死亡和并发症。这项工作的目的是测量慢性粒细胞白血病患者的血清雌激素及其可溶性受体水平，以推断其可能的临床意义。本研究包括 40 名（20 名男性和 20 名女性）临床上没有任何疾病的健康志愿者，40 名（20 名男性和 20 名女性）新诊断的 CML 患者。从所有受试者采集血样，并通过酶联免疫吸附测定 (ELISA) 测量血清雌激素 (E2) 和血清可溶性雌激素受体 (ER) 的水平。男女CML患者组血清E2水平(pg/ml)均显着高于对照组。男女CML患者组血清ER(ng/ml)水平均显着低于对照组。估计 E2 和可溶性 ER 的血清水平具有信息诊断价值。估计 CML 患者的 E2 和可溶性 ER 血清水平对于决定在治疗方案中使用抗雌激素作为治疗靶点具有价值。